Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard [...]

For USA readers – Protect Our Department of Defense Prostate Cancer Funding

UPDATE June &, 2016 4:30 PM EST We won. The Durbin Amendment to save all cancer research funding at the Department of Defense passed 66-32, saving the Congressionally Directed Medical Research Program (CDMRP), which includes an important prostate cancer funding resource. Thank you to everyone from Malecare Cancer Support and all of our partner organizations [...]

Good News, The House Appropriations Committee Increases the Ask For The DoD PCRP Allocation for FY 2017

Today, I have some good news to share with you. Malecare, along with many other prostate cancer advocacy groups have been hard at work attempting to persuade members of Congress to not only maintain the Department of Defense Prostate Cancer Research Program (DoD PCRP), but to increase its funding for the next fiscal year. I [...]

Some Good Funding News for the Prostate Cancer Community

The US Congress has just published the proposed Omnibus Budget for 2016. The good news is that the proposed budget includes the restoration of the 13.2 million dollars to the Centers for Disease Control (CDC)  for Prostate Cancer Prevention and Education and it also includes 80 million dollars for the Department of Defense Prostate Cancer [...]

By |2015-12-17T14:01:36-05:00December 17th, 2015|Advanced Prostate Cancer, Advocacy, CDC, DOD, Uncategorized|0 Comments

View The Congressional Record And Read Senator McCain’s Attempt To Cut The DOD CDMRP

Yesterday, the United States Senate debated the Defense Spending Bill. As expected Senator McCain’s amendment came up for debate. I have attached a link to the Congressional Record, which includes both Senator McCain’s remarks against continuing support for the Congressionally Directed Medical Research Programs as well as Senator Durbin’s response.   If you are interested in [...]

What Does the Prostate Cancer CDMRP Do And Why Is It So Important?

The problems created by Senator McCain continue to be ever present.  Our friend, Senator Durbin has asked that we provide his office with additional background about the military nature of the research performed by the Congressionally Directed Medical Research Programs (CDMRP), including the Prostate Cancer Research Program (PCRP). In addition there is a very misguided [...]

Please Reach Out To Senator Pat Roberts If You Live In Kansas

I have just received an update on Senator McCain's amendment.  According to Senator Pat Robert’s office they need to hear from more individuals from Kansas on opposing #1482 (the McCain amendment)so if it comes up they can let the Senator know and inform his position. If you live in Kansas, have family in Kansas or friends [...]

We Need Your Story To Save The CDMRP – If You Have Benefitted From Xfigo, Xtandi or Zytiga Let Me Know

Most people don't know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY.  Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available? The DOD PCRP is directly [...]

CDMRP PCRP Passes A Hurdle For Its 2016 Funding

About one hour ago I received some good news from Zero pertaining to the Congressionally Directed Medical Research Program.   The HAC-D report of the FY2016 Defense Appropriations Bill has the Prostate Cancer Research Program funded at $80M. The full bill can be seen here : http://appropriations.house.gov/uploadedfiles/hrpt-114-hr-fy2016-defense.pdf and the CDMRP numbers are found on page 273. The [...]

Radiologic Progression Free Survival Might Predict Treatment Response and Survival

In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]